FINAL RESULTS OF CTONG 0806: A PHASE II TRIAL COMPARING PEMETREXED WITH GEFITINIB AS SECOND-LINE TREATMENT OF ADVANCED NON-SQUAMOUS NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0

作者：

Zhou, Qing ^{[1
,2
]}

Cheng, Ying ^{[3
]}

Zhao, Ming-Fang ^{[4
]}

Yang, Jin-Ji ^{[1
,2
]}

Yan, Hong-Hong ^{[1
,2
]}

Zhang, Li ^{[5
]}

Song, Yong ^{[6
]}

Chen, Jian-Hua ^{[7
]}

Feng, Wei-Neng ^{[8
]}

Xu, Chong-Rui ^{[1
,2
]}

Wu, Yi-Long ^{[1
,2
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Jilin Prov Canc Hosp, Yanji, Peoples R China

[4] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[5] Perking Union Med Hosp, Beijing, Peoples R China

[6] Nanjing Univ Med, Jinling Hosp, Dept Resp Med, Nanjing, Jiangsu, Peoples R China

[7] Hunan Canc Hosp, Changsha, Hunan, Peoples R China

[8] First Peoples Hosp Foshan, Foshan, Peoples R China

来源：

关键词：

non-small cell lung cancer; wild-type EGFR; pemetrexed; gefitinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O15.07

引用

页码：S194 / S195

页数：2